The Immunological Therapeutic Strategies for Controlling Multiple Sclerosis: Considerations during the COVID-19 Pandemic.
COVID-19
disease-modifying therapies (DMTs)
multiple sclerosis (MS)
Journal
Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414
Informations de publication
Date de publication:
17 09 2021
17 09 2021
Historique:
received:
21
07
2021
revised:
31
08
2021
accepted:
13
09
2021
entrez:
28
9
2021
pubmed:
29
9
2021
medline:
5
10
2021
Statut:
epublish
Résumé
A growing body of evidence initially suggested that patients with multiple sclerosis (MS) might be more susceptible to coronavirus disease 2019 (COVID-19). Moreover, it was speculated that patients with MS treated with immunosuppressive drugs might be at risk to develop a severe diseases course after infection with the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV2). However, the recently published data have shown that MS patients do not have a higher risk for severe COVID-19. Although there is no indication that patients with MS and immunomodulatory/immunosuppressive therapy are generally at a higher risk of severe COVID-19, it is currently being emphasized that the hazards of poorly treated MS may outweigh the putative COVID-19 dangers. In this review, we discuss the challenges and considerations for MS patients in the COVID-19 pandemic.
Identifiants
pubmed: 34572585
pii: biom11091372
doi: 10.3390/biom11091372
pmc: PMC8470206
pii:
doi:
Substances chimiques
Immunosuppressive Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Mult Scler. 2016 Nov;22(13):1750-1758
pubmed: 26869531
Sci Rep. 2021 Mar 29;11(1):7052
pubmed: 33782412
J Neuroinflammation. 2019 Dec 23;16(1):272
pubmed: 31870389
J Clin Med. 2020 Jun 05;9(6):
pubmed: 32516940
PLoS One. 2013 Jun 19;8(6):e65835
pubmed: 23840373
Inflamm Regen. 2021 May 7;41(1):15
pubmed: 33962695
Neurol Neurochir Pol. 2020;54(6):490-501
pubmed: 33073348
Clin Infect Dis. 2020 Nov 19;71(16):2027-2034
pubmed: 32221519
Acta Neurol Scand. 2015;132(199):24-8
pubmed: 26046555
Neurol Sci. 2020 May;41(5):1007-1009
pubmed: 32303856
Mult Scler. 2020 Sep;26(10):1153-1156
pubmed: 32552382
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Neurology. 2020 Jun 2;94(22):949-952
pubmed: 32241953
Front Immunol. 2021 Jun 21;12:701752
pubmed: 34234787
Hong Kong Med J. 2016 Jun;22(3 Suppl 4):25-31
pubmed: 27390007
JAMA Neurol. 2020 Sep 1;77(9):1079-1088
pubmed: 32589189
Immunity. 2006 Feb;24(2):179-89
pubmed: 16473830
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
Noro Psikiyatr Ars. 2018;55(Suppl 1):S1-S9
pubmed: 30692847
Trends Immunol. 2009 Aug;30(8):409-14
pubmed: 19643667
Neurol Neuroimmunol Neuroinflamm. 2021 May 20;8(4):
pubmed: 34016734
Int Braz J Urol. 2020 Jul;46(suppl.1):6-18
pubmed: 32549071
Pediatr Allergy Immunol. 2001 Feb;12(1):4-10
pubmed: 11251858
Acta Neurol Belg. 2012 Dec;112(4):327-33
pubmed: 22767049
N Engl J Med. 2020 Dec 24;383(26):2586-2588
pubmed: 33259154
Signal Transduct Target Ther. 2020 Aug 31;5(1):179
pubmed: 32868756
Neurotoxicology. 2017 Jul;61:189-212
pubmed: 27045883
Nat Med. 2020 Apr;26(4):453-455
pubmed: 32284614
Brain Sci. 2020 Jun 04;10(6):
pubmed: 32512702
Clin Rev Allergy Immunol. 2020 Aug;59(1):89-100
pubmed: 32328954
Front Immunol. 2021 Apr 28;12:661052
pubmed: 33995382
Ther Adv Neurol Disord. 2021 Apr 22;14:17562864211012835
pubmed: 34035836
Clin Chem Lab Med. 2020 Jun 25;58(7):1131-1134
pubmed: 32119647
J Neuropathol Exp Neurol. 2003 Jul;62(7):723-32
pubmed: 12901699
Nat Med. 2014 May;20(5):524-30
pubmed: 24747744
Ann Clin Transl Neurol. 2019 Sep;6(9):1905-1922
pubmed: 31392849
PLoS Med. 2020 Sep 22;17(9):e1003346
pubmed: 32960881
Mult Scler. 2021 Mar 25;:13524585211005339
pubmed: 33764197
Mult Scler. 2021 May;27(6):864-870
pubmed: 33856242
Semin Immunopathol. 2016 Jul;38(4):471-82
pubmed: 26965109
Front Mol Biosci. 2020 Jul 03;7:157
pubmed: 32719810
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
Mult Scler Relat Disord. 2016 Nov;10:169-173
pubmed: 27919484
Br J Nutr. 2011 Nov;106(9):1433-40
pubmed: 21736791
Lancet Neurol. 2018 Feb;17(2):162-173
pubmed: 29275977
Nat Immunol. 2007 Sep;8(9):967-74
pubmed: 17581537
Acta Neurol Belg. 2012 Jun;112(2):133-40
pubmed: 22450711
Mult Scler. 2020 Sep;26(10):1134-1136
pubmed: 32924837
J Clin Invest. 2013 Jun;123(6):2737-41
pubmed: 23676463
Ann Neurol. 2011 Feb;69(2):292-302
pubmed: 21387374
Eur J Nutr. 2013 Jun;52(4):1405-15
pubmed: 23015061
J Allergy Clin Immunol Pract. 2020 May;8(5):1489-1491
pubmed: 32220575
Neurology. 2014 Jul 15;83(3):278-86
pubmed: 24871874
Mult Scler. 2020 Sep;26(10):1268-1269
pubmed: 32463329
Front Neurol. 2019 Mar 15;10:188
pubmed: 30930829
Immunity. 2020 Jun 16;52(6):910-941
pubmed: 32505227
J Infect. 2020 Jun;80(6):656-665
pubmed: 32283155
Mult Scler. 2020 Sep;26(10):1264-1266
pubmed: 32762488
Int Immunopharmacol. 2020 Oct;87:106808
pubmed: 32693359
Lancet Neurol. 2018 Jun;17(6):498
pubmed: 29778358
J Clin Med. 2020 Dec 16;9(12):
pubmed: 33339436
Eur J Neurol. 2021 Oct;28(10):3369-3374
pubmed: 32978860
CNS Drugs. 2021 Mar;35(3):317-330
pubmed: 33743151
Mult Scler. 2020 Sep;26(10):1256-1260
pubmed: 32662742
Nat Rev Immunol. 2005 Dec;5(12):917-27
pubmed: 16322745
Signal Transduct Target Ther. 2020 Mar 27;5(1):33
pubmed: 32296069
Epidemiol Infect. 2006 Dec;134(6):1129-40
pubmed: 16959053
J Autoimmun. 2001 May;16(3):309-18
pubmed: 11334497
J Microbiol Immunol Infect. 2020 Jun;53(3):368-370
pubmed: 32205092
Expert Rev Clin Immunol. 2016 Oct;12(10):1069-89
pubmed: 27191526
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Neurobiol Dis. 2015 Feb;74:14-24
pubmed: 25448765
Front Immunol. 2020 May 01;11:827
pubmed: 32425950
Mult Scler. 2020 Sep;26(10):1267
pubmed: 32762499
Signal Transduct Target Ther. 2020 Jul 25;5(1):128
pubmed: 32712629
Eur J Neurol. 2021 Nov;28(11):3742-3748
pubmed: 34288285
BMC Infect Dis. 2021 Mar 11;21(1):256
pubmed: 33706699
Neurol Sci. 2020 Sep;41(9):2315-2316
pubmed: 32638135
Mult Scler. 2020 Sep;26(10):1261-1264
pubmed: 32762494
Int J Biol Sci. 2020 Mar 15;16(10):1678-1685
pubmed: 32226285
Mult Scler J Exp Transl Clin. 2018 Jun 26;4(2):2055217318783347
pubmed: 30090637
Immunol Lett. 2014 Mar-Apr;158(1-2):134-42
pubmed: 24412596
Natl Sci Rev. 2020 Jun;7(6):998-1002
pubmed: 34676125
Scott Med J. 2020 Nov;65(4):127-132
pubmed: 32807018
EBioMedicine. 2020 May;55:102763
pubmed: 32361250
Nat Rev Immunol. 2020 May;20(5):277
pubmed: 32249845
Mult Scler Relat Disord. 2020 Sep;44:102282
pubmed: 32554288
Immun Ageing. 2021 Apr 14;18(1):18
pubmed: 33853634
Cell Discov. 2020 May 4;6:31
pubmed: 32377375
Cell Mol Immunol. 2020 May;17(5):541-543
pubmed: 32203186
Mult Scler Relat Disord. 2020 Aug;43:102195
pubmed: 32460086
J Nurse Pract. 2021 Feb;17(2):218-221
pubmed: 33106751
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Front Immunol. 2020 May 12;11:1059
pubmed: 32477373
Mult Scler Relat Disord. 2020 Aug;43:102222
pubmed: 32464586
Neurotherapeutics. 2021 Jul;18(3):1602-1622
pubmed: 33880738
J Neuroimmunol. 2021 Jul 15;356:577599
pubmed: 34000472
Pract Neurol. 2011 Oct;11(5):283-8
pubmed: 21921003
Mult Scler Relat Disord. 2020 Jul;42:102185
pubmed: 32408147
Lancet Neurol. 2019 Mar;18(3):269-285
pubmed: 30679040
Mult Scler Relat Disord. 2020 Jul;42:102120
pubmed: 32315980